Biocon Posts Rs 25 Crore Profit in Q3 FY25
By Rediff Money Desk, New Delhi Jan 30, 2025 22:35
Biocon reported a net profit of Rs 25 crore in Q3 FY25, driven by growth in biosimilars and research services. The company's total income stood at Rs 3,821 crore. Read more.

New Delhi, Jan 30 (PTI) Biotech firm Biocon on Thursday reported a net profit of Rs 25 crore for the October-December quarter of 2024-25.
The Bengaluru-based firm had reported a net profit of Rs 660 crore in the October-December period of the previous fiscal year, largely driven exceptional gains of Rs 425.4 crore related to its investment in Bicara Therapeutics.
The company stated that results were not comparable due to exceptional items.
Total income of the company was Rs 3,821 crore in the third quarter against Rs 3,954 crore in the year-ago period, Biocon Ltd said in a regulatory filing.
"The Biocon Group reported Q3FY25 operating revenue of Rs 3,821 crore, with performance driven by a sustained double-digit growth of 14 per cent on a like-for-like basis in biosimilars and a return to growth in research services, which grew by 11 per cent," Biocon Group Chairperson Kiran Mazumdar-Shaw said.
The growth trajectory is clearly visible with sequential growth across all the three business segments this quarter, she added.
EBITDA at Rs 787 crore, reported a growth of 16 per cent while profit before tax and exceptional items at Rs 138 crore, improved significantly from a marginal loss last year, on a like-for-like basis, Mazumdar-Shaw stated.
"Syngene's return to growth, combined with global approvals for bUstekinumab and European approval for gLiraglutide, will pave the way for launches and drive growth in Q4 and beyond. These developments will strategically position the Biocon Group for enhanced long-term growth," she added.
The company in the filing explained that during the quarter ended December 31, 2023 and year ended March 31, 2024, pursuant to fund raise by Bicara
Therapeutics Inc, (Bicara), the Group's interest in Bicara was diluted thereby resulting in loss of significant influence over the investee.
Consequently, the Group fair valued its investment resulting in a gain of Rs 12.3 crore and Rs 425.4 crore in the standalone and consolidated financial results, respectively, and was disclosed under 'Other income'.
Prior to the Series C financing, the Group accounted for its investments in Bicara using the equity method as it had significant influence.
Consequently, the Group recorded dilution gain of Rs 105.3 crore for the year ended March 31, 2024, disclosed under 'Other income' in the consolidated financial results.
During the quarter and nine months ended December 31, 2024, the Group has recorded a fair value loss of Rs 352.4 crore and fair value gain of Rs 236.4 crore , respectively, within "Other Comprehensive Income" in the consolidated financial results, the filing said.
Biocon shares on Thursday ended 0.44 per cent up at Rs 357.15 apiece on BSE.
The Bengaluru-based firm had reported a net profit of Rs 660 crore in the October-December period of the previous fiscal year, largely driven exceptional gains of Rs 425.4 crore related to its investment in Bicara Therapeutics.
The company stated that results were not comparable due to exceptional items.
Total income of the company was Rs 3,821 crore in the third quarter against Rs 3,954 crore in the year-ago period, Biocon Ltd said in a regulatory filing.
"The Biocon Group reported Q3FY25 operating revenue of Rs 3,821 crore, with performance driven by a sustained double-digit growth of 14 per cent on a like-for-like basis in biosimilars and a return to growth in research services, which grew by 11 per cent," Biocon Group Chairperson Kiran Mazumdar-Shaw said.
The growth trajectory is clearly visible with sequential growth across all the three business segments this quarter, she added.
EBITDA at Rs 787 crore, reported a growth of 16 per cent while profit before tax and exceptional items at Rs 138 crore, improved significantly from a marginal loss last year, on a like-for-like basis, Mazumdar-Shaw stated.
"Syngene's return to growth, combined with global approvals for bUstekinumab and European approval for gLiraglutide, will pave the way for launches and drive growth in Q4 and beyond. These developments will strategically position the Biocon Group for enhanced long-term growth," she added.
The company in the filing explained that during the quarter ended December 31, 2023 and year ended March 31, 2024, pursuant to fund raise by Bicara
Therapeutics Inc, (Bicara), the Group's interest in Bicara was diluted thereby resulting in loss of significant influence over the investee.
Consequently, the Group fair valued its investment resulting in a gain of Rs 12.3 crore and Rs 425.4 crore in the standalone and consolidated financial results, respectively, and was disclosed under 'Other income'.
Prior to the Series C financing, the Group accounted for its investments in Bicara using the equity method as it had significant influence.
Consequently, the Group recorded dilution gain of Rs 105.3 crore for the year ended March 31, 2024, disclosed under 'Other income' in the consolidated financial results.
During the quarter and nine months ended December 31, 2024, the Group has recorded a fair value loss of Rs 352.4 crore and fair value gain of Rs 236.4 crore , respectively, within "Other Comprehensive Income" in the consolidated financial results, the filing said.
Biocon shares on Thursday ended 0.44 per cent up at Rs 357.15 apiece on BSE.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.05 ( -2.66)
- 30377649
- Thinkink Picturez
- 0.34 (+ 3.03)
- 21448692
- GTL Infrastructure
- 1.65 (+ 1.23)
- 11873393
- G G Engineering
- 1.11 (+ 4.72)
- 10014783
- Spright Agro
- 6.78 (+ 4.95)
- 8518832
MORE NEWS

Jio Financial, Zomato Join Nifty 50 - NSE Index...
Jio Financial Services and Zomato will enter the Nifty 50 index from March 28,...

Vedanta Wins Bid for Diamond Mine in Madhya...
Vedanta Ltd has emerged as the preferred bidder for a diamond mine in Madhya Pradesh,...

Brigade Group to Invest Rs 1,500 Cr in Kerala |...
Brigade Group, a property developer, has expressed interest in investing Rs 1,500 crore...